maritide glp-1 treatments are changing the game—not just for weight loss, but for overall metabolic health. Originally developed for type 2 diabetes, these medications are now helping people improve blood sugar control, reduce Amgen's Once-Monthly GLP-1 Agonist MariTide

In addition to the previously discussed UK data [10], experiences from Australia, Brazil, and France have demonstrated favorable safety profiles, sustained weight loss, and improvement in obesity-related comorbidities, particularly among patients with a BMI of 3040 kg/m 2 or with contraindications to surgery [27,28,29]

[2] [3] This approach requires careful consideration of your overall treatment goals, other medical conditions, and NICE guidance for your specific situation

Mechanisms of Action and Benefit Biological, Physiological, and Molecular Considerations Glucagon-like peptide 1 (GLP-1) is primarily secreted by enteroendocrine L-cells in the intestine, pancreatic -cells, and the central nervous system (CNS) [26]

10.1111/dom.12230 14 Gonzalez-PerezA.SchliengerR

however, pica (consumption of nonnutritive materials), a rodent correlate of nausea 47 , was more frequently observed with exendin-4 administration (Fig